Scientists at the Johns Hopkins Kimmel Cancer Center say they have preliminary evidence in laboratory-grown, human airway cells that a condensed form of cigarette smoke triggers so-called “epigenetic” changes in the cells consistent with the earliest steps toward lung cancer development.
You are here
Coverage of the latest news and updates from the field of stem cells.
India’s Department of Biotechnology announced that it has implemented a cooperative program with Japan to accelerate the application of stem cell technology in human disease with four institutions from India participating with the Centre for iPS Cell Research and Application (CiRA), Kyoto Univers
Scientists at the Scripps Research Institute (SRI) have found a new approach to the “reprogramming” of ordinary adult cells into stem cells.
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Cellect Biotechnology Ltd.'s ApoGraft™ for the prevention of acute and chronic graft versus host disease(GvHD) in transplant patients. Cellect is a developer of stem cells selection technology.
Macular degeneration is the leading cause of vision loss in older adults, but scientists have long struggled to study and replicate key elements of the disease in the lab.
While Zika virus causes devastating damage to the brains of developing fetuses, it one day may be an effective treatment for glioblastoma, a deadly form of brain cancer. New research from Washington University School of Medicine in St.
Longeveron LLC, a regenerative medicine company developing cellular therapies, has treated its first patient in a Phase 2b clinical trial evaluating the safety and efficacy of its human allogeneic mesenchymal stem cells (LMSCs) in patients with aging frailty syndrome. Aging frailty is a comm
Scientists working to develop new treatments for neurodegenerative diseases have been stymied by the inability to grow human motor neurons in the lab.
Scientists at Children's Hospital of Philadelphia (CHOP) report that a drug candidate that blocks abnormal protein signals may lead to the first pharmacologic treatment for hereditary multiple exostoses (HME), a rare pediatric genetic disease.
The U.S. Food and Drug Administration took what it called “decisive action to prevent the use of a potentially dangerous and unproven treatment” belonging to StemImmune Inc.